You should reconsider investing in biotechs with such views. The Rett trial failed, and no regulator would approve it anywhere with these outcomes. They may go for another trial, but this would add a minimum of five years to the timeline, and likely that trial would fail as well. The Rett programme is dead for 2-73. The quicker people realise that, the better. Everything Anavex now has is the EMA submission, which in my view was speculative and unrealistic. However, this has less than 1% chance of approval with the data we have seen, imo. But it seems it works for Missling in terms of keeping the mcap that high.
News 
Market Data 
Discover 
